Stay updated with breaking news from Oncoextra Test. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) have received a consensus rating of “Moderate Buy” from the fifteen analysts that are covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 12-month price […]
Exact Sciences (NASDAQ:EXAS – Free Report) had its target price decreased by Piper Sandler from $90.00 to $80.00 in a research note issued to investors on Monday, Benzinga reports. Piper Sandler currently has an overweight rating on the medical research company’s stock. A number of other research firms have also weighed in on EXAS. The […]
Private Trust Co. NA acquired a new stake in Exact Sciences Co. (NASDAQ:EXAS – Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 480 shares of the medical research company’s stock, valued at approximately $45,000. A number of other institutional investors and […]
Credit Agricole S A lifted its position in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 183.3% during the second quarter, Holdings Channel reports. The firm owned 7,790 shares of the medical research company’s stock after acquiring an additional 5,040 shares during the period. Credit Agricole S A’s holdings in Exact Sciences were […]
IFM Investors Pty Ltd lifted its position in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 19.8% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 37,543 shares of the medical research company’s stock after purchasing an additional 6,208 shares during the quarter. IFM Investors […]